DE69841938D1 - Zyklische agonisten des crf - Google Patents
Zyklische agonisten des crfInfo
- Publication number
- DE69841938D1 DE69841938D1 DE69841938T DE69841938T DE69841938D1 DE 69841938 D1 DE69841938 D1 DE 69841938D1 DE 69841938 T DE69841938 T DE 69841938T DE 69841938 T DE69841938 T DE 69841938T DE 69841938 D1 DE69841938 D1 DE 69841938D1
- Authority
- DE
- Germany
- Prior art keywords
- phe12
- glu30
- cyclo
- nle21
- lys33
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000556 agonist Substances 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 abstract 1
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 abstract 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- LJGOZJHDEQHJRI-SITYYSIOSA-N α-helical crf Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(C)C)C1=CNC=N1 LJGOZJHDEQHJRI-SITYYSIOSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5751—Corticotropin releasing factor [CRF] (Urotensin)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/865,772 US5824771A (en) | 1994-12-12 | 1997-05-30 | Cyclic CRF agonists |
| PCT/US1998/010720 WO1998054222A1 (en) | 1997-05-30 | 1998-05-27 | Cyclic crf agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69841938D1 true DE69841938D1 (de) | 2010-11-25 |
Family
ID=25346194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69841938T Expired - Lifetime DE69841938D1 (de) | 1997-05-30 | 1998-05-27 | Zyklische agonisten des crf |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5824771A (https=) |
| EP (1) | EP0988320B1 (https=) |
| JP (1) | JP4166289B2 (https=) |
| AT (1) | ATE484521T1 (https=) |
| AU (1) | AU7599798A (https=) |
| DE (1) | DE69841938D1 (https=) |
| WO (1) | WO1998054222A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326463B1 (en) * | 1994-12-12 | 2001-12-04 | The Salk Institute For Biological Studies | Cyclic CRF agonists |
| WO2002024732A2 (en) * | 2000-09-22 | 2002-03-28 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften | Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr) |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| WO2003011823A2 (en) * | 2001-08-01 | 2003-02-13 | The Salk Institute For Biological Studies | Crfr1 selective ligands |
| US7192924B2 (en) * | 2002-01-16 | 2007-03-20 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| US6849600B2 (en) * | 2002-03-25 | 2005-02-01 | The Regents Of The University Of California, Berkeley | Corticotropin-releasing hormone analogs |
| US20090035298A1 (en) * | 2007-04-23 | 2009-02-05 | Washington University In St. Louis | Methods to treat alzheimer's disease or other amyloid beta accumulation associated disorders |
| EP2654772B1 (en) * | 2010-12-22 | 2018-09-26 | The Salk Institute for Biological Studies | Cyclic crf antagonist peptides |
| EP3379222B1 (en) | 2017-03-22 | 2020-12-30 | Methode Electronics Malta Ltd. | Magnetoelastic based sensor assembly |
| US11221262B2 (en) | 2018-02-27 | 2022-01-11 | Methode Electronics, Inc. | Towing systems and methods using magnetic field sensing |
| US11135882B2 (en) | 2018-02-27 | 2021-10-05 | Methode Electronics, Inc. | Towing systems and methods using magnetic field sensing |
| US10670479B2 (en) | 2018-02-27 | 2020-06-02 | Methode Electronics, Inc. | Towing systems and methods using magnetic field sensing |
| US11084342B2 (en) | 2018-02-27 | 2021-08-10 | Methode Electronics, Inc. | Towing systems and methods using magnetic field sensing |
| US11014417B2 (en) | 2018-02-27 | 2021-05-25 | Methode Electronics, Inc. | Towing systems and methods using magnetic field sensing |
| US11491832B2 (en) | 2018-02-27 | 2022-11-08 | Methode Electronics, Inc. | Towing systems and methods using magnetic field sensing |
| GB201816621D0 (en) | 2018-10-12 | 2018-11-28 | Univ Leuven Kath | Prevention or treatment of adrenal insuffiency in critically ill patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4632789A (en) * | 1985-01-31 | 1986-12-30 | Reid Philip L | Gas humidification apparatus |
| US5109111A (en) * | 1988-09-23 | 1992-04-28 | The Salk Institute For Biological Studies | CRF antagonists |
| CA1340964C (en) * | 1988-09-30 | 2000-04-18 | Jean E. F. Rivier | Crf analogs |
| US5278146A (en) * | 1988-09-30 | 1994-01-11 | The Salk Institute For Biological Studies | CRF analogs |
| US5064939A (en) * | 1990-02-06 | 1991-11-12 | The Salk Institute For Biological Studies | Cyclic gnrh antagonists |
| US5235036A (en) * | 1991-05-31 | 1993-08-10 | The Salk Institute For Biological Studies | Crf analogs |
| US5245009A (en) * | 1990-03-23 | 1993-09-14 | The Salk Institute For Biological Studies | CRF antagonists |
| US5493006A (en) * | 1993-06-16 | 1996-02-20 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
| US5663292A (en) * | 1994-12-12 | 1997-09-02 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
-
1997
- 1997-05-30 US US08/865,772 patent/US5824771A/en not_active Expired - Lifetime
-
1998
- 1998-05-27 DE DE69841938T patent/DE69841938D1/de not_active Expired - Lifetime
- 1998-05-27 AT AT98923787T patent/ATE484521T1/de not_active IP Right Cessation
- 1998-05-27 JP JP55078698A patent/JP4166289B2/ja not_active Expired - Fee Related
- 1998-05-27 WO PCT/US1998/010720 patent/WO1998054222A1/en not_active Ceased
- 1998-05-27 EP EP98923787A patent/EP0988320B1/en not_active Expired - Lifetime
- 1998-05-27 AU AU75997/98A patent/AU7599798A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US5824771A (en) | 1998-10-20 |
| JP4166289B2 (ja) | 2008-10-15 |
| EP0988320A1 (en) | 2000-03-29 |
| AU7599798A (en) | 1998-12-30 |
| ATE484521T1 (de) | 2010-10-15 |
| EP0988320B1 (en) | 2010-10-13 |
| JP2002511067A (ja) | 2002-04-09 |
| WO1998054222A1 (en) | 1998-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE484521T1 (de) | Zyklische agonisten des crf | |
| WO1996019499A3 (en) | Improved cyclic crf antagonists | |
| Odermatt et al. | Structural diversity and domain composition of a unique collagenous fragment (intima collagen) obtained from human placenta | |
| KR920016463A (ko) | 펩티드의 제조방법 | |
| Bailey et al. | Partial characterization of a second basement membrane collagen in human placenta: evidence for the existence of two type IV collagen molecules | |
| IE59488B1 (en) | Eukaryotic fusion proteins, the preparation and use there of, and means for carrying out the process | |
| NO965411L (no) | N-terminalt forlengede proteiner uttrykt i gjær | |
| NO963225L (no) | Multivariant IL-3 hematopoiese-fusjonsprotein | |
| DK0479912T3 (da) | Fremgangsmåde til hæmning af N-endereglens forløb i levende celler | |
| DE3875538D1 (de) | Aminoluciferine, verfahren zu deren herstellung und ihre verwendung. | |
| DE3486154D1 (de) | Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung. | |
| ES2095255T3 (es) | Analogos de sustitucion de peptidos magainina. | |
| ES8700272A1 (es) | Procedimiento para la preparacion y purificacion de peptidos | |
| Knight et al. | A collagenous glycoprotein found in dissociative extracts of foetal bovine nuchal ligament. Evidence for a relationship with type VI collagen | |
| DK0794255T3 (da) | Fremgangsmåde til spaltning af kimært protein ved anvendelse af processeringsenzym | |
| PE47599A1 (es) | Proteinas antiobesidad | |
| Timpl et al. | Cyanogen bromide cleavage of bovine fibrinogen. Identification of a dimeric N-terminal peptide and two other disulfide containing fragments | |
| Sasaki et al. | Chemical studies on the isolated collagen-like and globular fragments of complement component C1q comparative studies on bovine and human C1q | |
| Hackeng et al. | Chemical synthesis of human protein S thrombin‐sensitive module and first epidermal growth factor module | |
| PL316069A1 (en) | Novel derivatives of biotin and method of obtaining them as well as pharmaceutic preparation and method of preparing same | |
| WO2003046160A3 (en) | Methods of increasing protein expression levels | |
| Kimura et al. | Total synthesis of human parathyroid hormone (1–84) | |
| DK196086A (da) | Fremgangsmaade til fremstilling af et protein | |
| MITRA et al. | Temperature-induced conformational changes in prosomatostatin-II: implications for processing | |
| Berrini et al. | Purification to homogeneity of bovine prolactin by high-performance ion-exchange chromatography |